ATLAS ACS2-TIMI 51

ATLAS ACS 2-TIMI 51 was a phase III, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating an oral, direct factor Xa inhibitor (rivaroxaban) in subjects following an acute coronary syndrome. Subjects received low-dose aspirin therapy (75 to 100 mg/day), and enrollment was stratified based upon the intent of the investigator to administer a thienopyridine [Stratum 1 (aspirin only) and Stratum 2 (aspirin plus a thienopyridine)]. Two different doses of rivaroxaban were tested: 2.5 mg twice a day and 5.0 mg twice a day.

Screenshot_2021-02-03 Microsoft PowerPoint - ATLAS_ACS_2_TIMI_51_Presentation_Slides1 [Compatibility Mode] - timi-51-slides[...]

MAIN RESULTS:
Rivaroxaban in patients with a recent acute coronary syndrome
ATLAS ACS2-TIMI 51
N Engl J Med. 2012 Jan 5;366(1):9-19.

PRESENTATIONS

TIMI 51 Slides
Atlas ACS2-TIMI 51 Poster (Alkhalfan AHA 2019)

OTHER PUBLICATIONS

Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am Heart J. 2011 May;161(5):815-821.e6.

Rivaroxaban in Patients Stabilized after a ST-Elevation Myocardial Infarction: Results from the ATLAS ACS 2-TIMI 51 Trial. J Am Coll Cardiol. 2013 May 7;61(18):1853-9.

Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. J Am Coll Cardiol. 2013 Jul 23;62(4):286-90.

Comparison of the Efficacy and Safety of Two Rivaroxaban Doses in Acute Coronary Syndrome (from ATLAS ACS 2-TIMI 51). Am J Cardiol. 2013 Aug 15;112(4):472-8.

The Role of Rivaroxaban in Atrial Fibrillation and Acute Coronary Syndromes. J Cardiovasc Pharmacol Ther. 2014 Nov;19(6):526-32.

The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 – TIMI 51 trial. Eur Heart J Acute Cardiovasc Care. 2015 Oct;4(5):468-74.

Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. Eur Heart J Acute Cardiovasc Care. 2019 Mar;8(2):186-193.

Rivaroxaban and Post-Stroke Neurological Outcomes in Patients With Acute Coronary Syndrome. J Am Coll Cardiol. 2018 Mar 6;71(9):1048-1049.

D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy). Am J Cardiol. 2018 Nov 1;122(9):1459-1464.

Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. Eur Heart J. 2018 Nov 7;39(42):3810-3820.

Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. J Am Coll Cardiol. 2019 Dec 17;74(24):3013-3022.

Relation of White Blood Cell Count to Bleeding and Ischemic Events in Patients With Acute Coronary Syndrome (from the ATLAS ACS 2-TIMI 51 Trial). Am J Cardiol. 2020 Mar 1;125(5):661-669.

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close